The MemTrax team has been researching and developing innovative ways to investigate and measure the human brain.
Our vast network of talent has led the Alzheimer's disease and dementia research community for years.
The most well funded researchers in the world use MemTrax because it is simple, fun, and reliable.
he idea that being proactive and preventative about your cognition and brain health is critical for a long happy life.
By using our free online memory test users are able to take a quick interactive cognitive test and watch their results on special graphs and charts we have developed.
MemTrax is a family founded business created to motivate and inspire people in taking a proactive and preventative approach to caring for their brain health. Our mission is to continue to develop innovative cognitive assessments that are fun and repeatable while advancing research to better understand the human brain
Please reach out if you might have any questions.
This document presents an overview of the AI applications in life sciences. The presentation highlights various steps in drug development and AI applications. Also, discusses Alzheimer’s disease and obstacles to develop drugs. Finally, presents details of AI in target identification for AD.
This disclaimer informs readers know that the views, thoughts, and opinions expressed in the presentation belong solely to the author, and not to the author’s employer, organization, committee or other group or individual.
Best practices to assess and enhance brain function via mobile devices and ...SharpBrains
The document discusses best practices for assessing and enhancing brain function using mobile devices and wearables. It summarizes presentations from several speakers at a conference on this topic. Corinna Lathan discussed a mobile reaction time testing system called DANA that can help detect neurocognitive impairment. Eddie Martucci discussed his company Akili's approach of making medicine more engaging through digital games. Alex Doman talked about how wearables can provide personalized sleep reporting. Joan Severson presented on her company's BrainBaseline platform, which integrates cognitive performance measures with lifestyle data to track brain health over time.
A Vision for a National Research Network Brian Ahier
The document discusses the vision for a National Patient-Centered Research Network that would help address challenges with clinical research. It would bring together 20-30 million people with diverse characteristics and broad consent for research using their electronic health records over many years. This would allow for more efficient observational studies and randomized trials on topics like mobile health applications, low back pain treatments, and large-scale pharmacogenomics. The network could significantly reduce research costs and help engage more of the public in medical research. Now is a good time to pursue this vision as electronic health records are more widely used and opportunities for clinical questions are greater.
Data Science Deep Roots in Healthcare IndustryDinesh V
Data Science transforms the healthcare industry with impeccable solutions that can improve patient care through EHRs, medical imaging, drug discovery, predictive medicines and genetics and genomics.
How to address privacy, ethical and regulatory issues: Examples in cognitive ...SharpBrains
How to address privacy, ethical and regulatory issues: Examples in cognitive enhancement, depression and ADHD
Dr. Karen Rommelfanger, Director of the Neuroethics Program at Emory University
Dr. Anna Wexler, Assistant Professor at the Perelman School of Medicine at UPenn
Jacqueline Studer, Senior VP and General Counsel of Akili Interactive Labs
Chaired by: Keith Epstein, Healthcare Practice Leader at Blue Heron
Slidedeck supporting presentation and discussion during the 2019 SharpBrains Virtual Summit: The Future of Brain Health (March 7-9th). Learn more at:
https://sharpbrains.com/summit-2019/
This document presents an overview of the AI applications in life sciences. The presentation highlights various steps in drug development and AI applications. Also, discusses Alzheimer’s disease and obstacles to develop drugs. Finally, presents details of AI in target identification for AD.
This disclaimer informs readers know that the views, thoughts, and opinions expressed in the presentation belong solely to the author, and not to the author’s employer, organization, committee or other group or individual.
Best practices to assess and enhance brain function via mobile devices and ...SharpBrains
The document discusses best practices for assessing and enhancing brain function using mobile devices and wearables. It summarizes presentations from several speakers at a conference on this topic. Corinna Lathan discussed a mobile reaction time testing system called DANA that can help detect neurocognitive impairment. Eddie Martucci discussed his company Akili's approach of making medicine more engaging through digital games. Alex Doman talked about how wearables can provide personalized sleep reporting. Joan Severson presented on her company's BrainBaseline platform, which integrates cognitive performance measures with lifestyle data to track brain health over time.
A Vision for a National Research Network Brian Ahier
The document discusses the vision for a National Patient-Centered Research Network that would help address challenges with clinical research. It would bring together 20-30 million people with diverse characteristics and broad consent for research using their electronic health records over many years. This would allow for more efficient observational studies and randomized trials on topics like mobile health applications, low back pain treatments, and large-scale pharmacogenomics. The network could significantly reduce research costs and help engage more of the public in medical research. Now is a good time to pursue this vision as electronic health records are more widely used and opportunities for clinical questions are greater.
Data Science Deep Roots in Healthcare IndustryDinesh V
Data Science transforms the healthcare industry with impeccable solutions that can improve patient care through EHRs, medical imaging, drug discovery, predictive medicines and genetics and genomics.
How to address privacy, ethical and regulatory issues: Examples in cognitive ...SharpBrains
How to address privacy, ethical and regulatory issues: Examples in cognitive enhancement, depression and ADHD
Dr. Karen Rommelfanger, Director of the Neuroethics Program at Emory University
Dr. Anna Wexler, Assistant Professor at the Perelman School of Medicine at UPenn
Jacqueline Studer, Senior VP and General Counsel of Akili Interactive Labs
Chaired by: Keith Epstein, Healthcare Practice Leader at Blue Heron
Slidedeck supporting presentation and discussion during the 2019 SharpBrains Virtual Summit: The Future of Brain Health (March 7-9th). Learn more at:
https://sharpbrains.com/summit-2019/
Brain Health in the Pervasive Neurotechnology EraSharpBrains
This document summarizes presentations from a conference on brain health and neurotechnology. It discusses how digital tools and neuroplasticity can be used to enhance work and life. Several speakers presented on their research and programs. Posit Science discussed cognitive training programs that reduced car crash rates in older adults. eMindful discussed their live, online mindfulness programs and research showing benefits like decreased stress and improved brain function. Applied Cognitive Engineering discussed their cognitive simulation training programs and case studies showing benefits for sports performance, including USA hockey winning several international titles after adopting their program.
The Quahog Decision Platform aims to save over a million lives each year by improving medical diagnosis and decision-making. It does this by creating a centralized data infrastructure that collects and unifies medical data from various sources. This unified data set allows machine learning algorithms to analyze relationships between all relevant health parameters and arrive at the most accurate diagnosis within minutes. The platform also aims to enable personalized treatment, faster diagnosis, preventive care through predictions, monitoring of treatment effectiveness, and insights to support new medical research and innovations.
A Call to Action: Improving brain & mental health via digital platforms,...SharpBrains
(Session held at the 2014 SharpBrains Virtual Summit; October 28-30th, 2014)
8:15–9:45am. A Call to Action: Improving brain & mental health via digital platforms, neuroplasticity research and the White House BRAIN initiative
- Dr. Thomas Insel, Director of the National Institute of Mental Health (NIMH)
- Dr. Adam Gazzaley, Director of UCSF Neuroscience Imaging Center and Co-founder of Akili Interactive Labs
- Dr. Daphne Bavelier, Head of the Brain & Learning Lab at the University of Geneva & U. of Rochester
- Jack Young, Head of Qualcomm Life Fund
- Chair: Alvaro Fernandez, CEO of SharpBrains
Learn more here:
http://sharpbrains.com/summit-2014/agenda/
Healthcare is undergoing a technological transformation, and it is imperative for the industry to leverage new technologies to generate, collect, and track novel data. Panel chaired by Ralf Reilmann of the George Huntington Institut, Muenster.
Data Infrastructure for Real-time Analysis to provide Health InsightsQuahog Life Sciences
Illustrating how a well planned data infrastructure designed for real-time and continuous learning can have multiple advantages, facilitating better preventive strategies
InSyBio is developing an integrated cloud platform for biomarker discovery to improve precision medicine and clinical trials. Their platform performs end-to-end biomarker analysis from raw biological data through extraction, interpretation and applications. This is more efficient than existing fragmented methods. InSyBio's biomarkers are highly accurate with small sample sizes and can reduce clinical trial costs and times. Their platform has applications in nutrition, pharma and diagnostics.
At the frontier of Big Data and Brain HealthSharpBrains
During this session we will explore cutting-edge initiatives to accelerate research & development via Big Data, crowdsourcing, technologies for the extended mind, and a range of data-rich pervasive neurotechnologies such as virtual reality.
-Chair: Alison Fenney, Director of Industry Alliances at the Neurotechnology Industry Organization (NIO)
-Dr. Walter Greenleaf, Distinguished Visiting Scholar at Stanford University’s Virtual Human Interaction Lab
-Michael Meagher, President of Cogniciti
-José Barrios, Co-Founder & CEO of Cognilab
-Dr. Peter Reiner, Co-Founder, National Core for Neuroethics at the University of British Columbia
Presentation @ The 2015 SharpBrains Virtual Summit http://sharpbrains.com/summit-2015/agenda
Innowave Freedom Clearing House /freedom Nano users can have single-click access to Neuroshield™,
Neuroshield™ is a Clinical Decision Support Tool for Neurological Disorders, A comprehancive tool to
evealuate Qualitative and Quantitative conditions of the Human Brain. Neuroshield™ is a product from
“In-Med Prognostics“Is a company with leadership in, reliable and data-driven brain health diagnostic and
prognostic tools
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
This document discusses quality improvement in healthcare. It begins by posing questions about defining quality, what quality improvement is, and how quality can be improved. It then discusses the safety paradox in healthcare - that despite highly trained staff and technology, errors are common and patients are frequently harmed. Several studies on adverse event rates in hospitals are summarized. The document discusses concepts for safety and quality improvement like reliability, variation, measurement, and change management. It provides examples of quality improvement tools and approaches like process mapping, care bundles, measurement, and the PDSA (Plan-Do-Study-Act) cycle. Overall, the document provides an overview of key issues and approaches related to quality and safety in healthcare.
Predicting Chronic Kidney Disease using Data Mining Techniquesijtsrd
Kidney is a significant aspect of a human body. Kidney infection or disappointments are expanded in every year. Presently a day’s chronic kidney infection is the most well known disease for the individuals. Today numerous individuals pass on due to chronic kidney disease. The principle issue of CKD is, it will influence the kidney gradually. A few people dont have side effects at all and are analysed by a lab test. It depicts the steady loss of kidney work. Early recognition and therapy are viewed as basic variables in the management and control of chronic kidney disease. Data mining techniques is utilized to extract data from clinical and laboratory, which can be useful to help doctors to recognize the seriousness stage of patients. Using Probabilistic Neural Networks PNN algorithm will get better prediction for determining the severity stage of chronic kidney disease. Seethal V | Kuldeep Baban Vayadande "Predicting Chronic Kidney Disease using Data Mining Techniques" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-1 , December 2020, URL: https://www.ijtsrd.com/papers/ijtsrd37974.pdf Paper URL : https://www.ijtsrd.com/computer-science/data-miining/37974/predicting-chronic-kidney-disease-using-data-mining-techniques/seethal-v
Presentation "The Impact of All Data on Healthcare"
Keith Perry
Associate VP & Deputy CIO
UT MD Anderson Cancer Center
With continuing advancement in both technology and medicine, the drive is on to make all data meaningful to drive medical discovery and create actionable outcomes. With tools and capabilities to capture more data than ever before, the challenge becomes linking existing structured and unstructured clinical data with genomic data to increase the industry’s analytical footprint.
Learning Objectives:
∙ Discuss the need to make all data meaningful in order to speed discovery of new knowledge
∙ Provide examples of an analytical direction that supports evolution in medicine
∙ Expose the challenges facing the industry with respect to ~omits
Predictive Analytics and Machine Learning for Healthcare - DiabetesDr Purnendu Sekhar Das
Machine Learning on clinical datasets to predict the risk of chronic disease conditions like Type 2 Diabetes mellitus beforehand; as well as predicting outcomes like hospital readmission using EMR RWE data.
Georgetown Innovation Center for Biomedical Informatics Symposium Precision ...Warren Kibbe
The document discusses opportunities and challenges with precision oncology and big data. It describes how big data from sources like mobile devices, social media, next generation sequencing, imaging, and electronic health records can be leveraged. Key challenges include needing synoptic and semantic EHR data to support precision medicine, and handling and analyzing large amounts of patient-derived data from various sources. Examples provided of current solutions include mobile apps to collect patient-reported outcomes and integrating natural language processing with EHRs. The document also describes several projects and tools developed at Northwestern University for mobile computing and context awareness in healthcare, such as Mobilyze for depression treatment and Purple Robot for sensor data collection.
CORD Rare Drug Conference, June 8 - 9, 2022
Opportunities and Challenges for Data Management Real-World Data and Real-World Evidence
• Patient support programs: Sandra Anderson, Innomar Strategies
• AI for Data Management and Enhancement: Aaron Leibtag, Pentavere
• Patient Support and RWE: Laurie Lambert, CADTH
The document discusses the emerging field of precision medicine and how it represents a shift from symptom-based to evidence-based to personalized medicine. Precision medicine utilizes large datasets including multi-omics data, imaging, and other clinical data combined with machine learning algorithms and pattern recognition to develop personalized molecular profiles and more precise diagnoses and treatments. Key challenges include the need for higher quality and standardized data as well as streamlined processes to validate findings and translate biomarker discovery into clinical applications.
The document discusses the emerging field of precision medicine and how it represents a shift from symptom-based to evidence-based to personalized medicine. Precision medicine utilizes large datasets including multi-omics data, imaging, and other clinical data combined with machine learning algorithms and reference databases to generate personalized molecular profiles and enable targeted prevention and treatment. Key to realizing precision medicine's potential is establishing standards, processes, and reference databases to facilitate large-scale data analysis and ensure results can be reproduced.
This document discusses secondary data analysis and provides examples of large federal health surveys that can be used for secondary analysis, including NHANES and NHIS. It outlines strengths and limitations of secondary data analysis. Complex survey design must be accounted for, including statistical weighting, clustering, and stratification. Several statistical software programs are designed for analyzing complex survey data. The document concludes with a hypothetical case study using NHIS and EPA air pollution exposure data to study the relationship between acrolein levels and childhood asthma episodes.
Brain Health in the Pervasive Neurotechnology EraSharpBrains
This document summarizes presentations from a conference on brain health and neurotechnology. It discusses how digital tools and neuroplasticity can be used to enhance work and life. Several speakers presented on their research and programs. Posit Science discussed cognitive training programs that reduced car crash rates in older adults. eMindful discussed their live, online mindfulness programs and research showing benefits like decreased stress and improved brain function. Applied Cognitive Engineering discussed their cognitive simulation training programs and case studies showing benefits for sports performance, including USA hockey winning several international titles after adopting their program.
The Quahog Decision Platform aims to save over a million lives each year by improving medical diagnosis and decision-making. It does this by creating a centralized data infrastructure that collects and unifies medical data from various sources. This unified data set allows machine learning algorithms to analyze relationships between all relevant health parameters and arrive at the most accurate diagnosis within minutes. The platform also aims to enable personalized treatment, faster diagnosis, preventive care through predictions, monitoring of treatment effectiveness, and insights to support new medical research and innovations.
A Call to Action: Improving brain & mental health via digital platforms,...SharpBrains
(Session held at the 2014 SharpBrains Virtual Summit; October 28-30th, 2014)
8:15–9:45am. A Call to Action: Improving brain & mental health via digital platforms, neuroplasticity research and the White House BRAIN initiative
- Dr. Thomas Insel, Director of the National Institute of Mental Health (NIMH)
- Dr. Adam Gazzaley, Director of UCSF Neuroscience Imaging Center and Co-founder of Akili Interactive Labs
- Dr. Daphne Bavelier, Head of the Brain & Learning Lab at the University of Geneva & U. of Rochester
- Jack Young, Head of Qualcomm Life Fund
- Chair: Alvaro Fernandez, CEO of SharpBrains
Learn more here:
http://sharpbrains.com/summit-2014/agenda/
Healthcare is undergoing a technological transformation, and it is imperative for the industry to leverage new technologies to generate, collect, and track novel data. Panel chaired by Ralf Reilmann of the George Huntington Institut, Muenster.
Data Infrastructure for Real-time Analysis to provide Health InsightsQuahog Life Sciences
Illustrating how a well planned data infrastructure designed for real-time and continuous learning can have multiple advantages, facilitating better preventive strategies
InSyBio is developing an integrated cloud platform for biomarker discovery to improve precision medicine and clinical trials. Their platform performs end-to-end biomarker analysis from raw biological data through extraction, interpretation and applications. This is more efficient than existing fragmented methods. InSyBio's biomarkers are highly accurate with small sample sizes and can reduce clinical trial costs and times. Their platform has applications in nutrition, pharma and diagnostics.
At the frontier of Big Data and Brain HealthSharpBrains
During this session we will explore cutting-edge initiatives to accelerate research & development via Big Data, crowdsourcing, technologies for the extended mind, and a range of data-rich pervasive neurotechnologies such as virtual reality.
-Chair: Alison Fenney, Director of Industry Alliances at the Neurotechnology Industry Organization (NIO)
-Dr. Walter Greenleaf, Distinguished Visiting Scholar at Stanford University’s Virtual Human Interaction Lab
-Michael Meagher, President of Cogniciti
-José Barrios, Co-Founder & CEO of Cognilab
-Dr. Peter Reiner, Co-Founder, National Core for Neuroethics at the University of British Columbia
Presentation @ The 2015 SharpBrains Virtual Summit http://sharpbrains.com/summit-2015/agenda
Innowave Freedom Clearing House /freedom Nano users can have single-click access to Neuroshield™,
Neuroshield™ is a Clinical Decision Support Tool for Neurological Disorders, A comprehancive tool to
evealuate Qualitative and Quantitative conditions of the Human Brain. Neuroshield™ is a product from
“In-Med Prognostics“Is a company with leadership in, reliable and data-driven brain health diagnostic and
prognostic tools
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
This document discusses quality improvement in healthcare. It begins by posing questions about defining quality, what quality improvement is, and how quality can be improved. It then discusses the safety paradox in healthcare - that despite highly trained staff and technology, errors are common and patients are frequently harmed. Several studies on adverse event rates in hospitals are summarized. The document discusses concepts for safety and quality improvement like reliability, variation, measurement, and change management. It provides examples of quality improvement tools and approaches like process mapping, care bundles, measurement, and the PDSA (Plan-Do-Study-Act) cycle. Overall, the document provides an overview of key issues and approaches related to quality and safety in healthcare.
Predicting Chronic Kidney Disease using Data Mining Techniquesijtsrd
Kidney is a significant aspect of a human body. Kidney infection or disappointments are expanded in every year. Presently a day’s chronic kidney infection is the most well known disease for the individuals. Today numerous individuals pass on due to chronic kidney disease. The principle issue of CKD is, it will influence the kidney gradually. A few people dont have side effects at all and are analysed by a lab test. It depicts the steady loss of kidney work. Early recognition and therapy are viewed as basic variables in the management and control of chronic kidney disease. Data mining techniques is utilized to extract data from clinical and laboratory, which can be useful to help doctors to recognize the seriousness stage of patients. Using Probabilistic Neural Networks PNN algorithm will get better prediction for determining the severity stage of chronic kidney disease. Seethal V | Kuldeep Baban Vayadande "Predicting Chronic Kidney Disease using Data Mining Techniques" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-1 , December 2020, URL: https://www.ijtsrd.com/papers/ijtsrd37974.pdf Paper URL : https://www.ijtsrd.com/computer-science/data-miining/37974/predicting-chronic-kidney-disease-using-data-mining-techniques/seethal-v
Presentation "The Impact of All Data on Healthcare"
Keith Perry
Associate VP & Deputy CIO
UT MD Anderson Cancer Center
With continuing advancement in both technology and medicine, the drive is on to make all data meaningful to drive medical discovery and create actionable outcomes. With tools and capabilities to capture more data than ever before, the challenge becomes linking existing structured and unstructured clinical data with genomic data to increase the industry’s analytical footprint.
Learning Objectives:
∙ Discuss the need to make all data meaningful in order to speed discovery of new knowledge
∙ Provide examples of an analytical direction that supports evolution in medicine
∙ Expose the challenges facing the industry with respect to ~omits
Predictive Analytics and Machine Learning for Healthcare - DiabetesDr Purnendu Sekhar Das
Machine Learning on clinical datasets to predict the risk of chronic disease conditions like Type 2 Diabetes mellitus beforehand; as well as predicting outcomes like hospital readmission using EMR RWE data.
Georgetown Innovation Center for Biomedical Informatics Symposium Precision ...Warren Kibbe
The document discusses opportunities and challenges with precision oncology and big data. It describes how big data from sources like mobile devices, social media, next generation sequencing, imaging, and electronic health records can be leveraged. Key challenges include needing synoptic and semantic EHR data to support precision medicine, and handling and analyzing large amounts of patient-derived data from various sources. Examples provided of current solutions include mobile apps to collect patient-reported outcomes and integrating natural language processing with EHRs. The document also describes several projects and tools developed at Northwestern University for mobile computing and context awareness in healthcare, such as Mobilyze for depression treatment and Purple Robot for sensor data collection.
CORD Rare Drug Conference, June 8 - 9, 2022
Opportunities and Challenges for Data Management Real-World Data and Real-World Evidence
• Patient support programs: Sandra Anderson, Innomar Strategies
• AI for Data Management and Enhancement: Aaron Leibtag, Pentavere
• Patient Support and RWE: Laurie Lambert, CADTH
The document discusses the emerging field of precision medicine and how it represents a shift from symptom-based to evidence-based to personalized medicine. Precision medicine utilizes large datasets including multi-omics data, imaging, and other clinical data combined with machine learning algorithms and pattern recognition to develop personalized molecular profiles and more precise diagnoses and treatments. Key challenges include the need for higher quality and standardized data as well as streamlined processes to validate findings and translate biomarker discovery into clinical applications.
The document discusses the emerging field of precision medicine and how it represents a shift from symptom-based to evidence-based to personalized medicine. Precision medicine utilizes large datasets including multi-omics data, imaging, and other clinical data combined with machine learning algorithms and reference databases to generate personalized molecular profiles and enable targeted prevention and treatment. Key to realizing precision medicine's potential is establishing standards, processes, and reference databases to facilitate large-scale data analysis and ensure results can be reproduced.
This document discusses secondary data analysis and provides examples of large federal health surveys that can be used for secondary analysis, including NHANES and NHIS. It outlines strengths and limitations of secondary data analysis. Complex survey design must be accounted for, including statistical weighting, clustering, and stratification. Several statistical software programs are designed for analyzing complex survey data. The document concludes with a hypothetical case study using NHIS and EPA air pollution exposure data to study the relationship between acrolein levels and childhood asthma episodes.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
1. Digital Cognitive Testing to Improve Healthcare
Measuring and monitoring Brain Health for early detection and data analysis
2. A thermometer for the Brain
How does the doctor currently measure your
cognition or memory when visiting for an
annual checkup?
A physician charges $100 to take your
temperature, a MemTrax test could be more
lucrative with similar common use application.
Billing for our cognitive test has several
options: From codes 92507 to 97130 there
are several options for execution.
● Critical for early treatment while
most effective
● Indicates earliest possible signs of
memory loss
● Tests the type of memory most
commonly associated with AD /
Dementia
● Repeatable on a regular basis - Fun
Early Detection is Critical
3. Research Support
Dr. Mike Weiner
Principal Investigator of ADNI
largest study in the world
concerning Alzheimer's Disease
Directed funds since 2004 - $120
million federal (NIA), $98 million
industry
Created the Brain Health Registry
featuring MemTrax
Researching for over 50 years and
passionate about open data sharing
http://adni.loni.usc.edu/about/
Charles J. Fuschillo, Jr.
President & Chief Executive Officer
of the Alzheimer’s Foundation of
America
New York State Senator for nearly 16
years
AFA created memory screening
efforts into a year-round National
Memory Screening Program that
provides free, confidential memory
screenings to individuals across the
country and is using MemTrax
https://alzfdn.org/team_member/charl
es-j-fuschillo-jr/
Dr. Frederick Schmitt
Professor of Neurology,
Neurosurgery, Psychiatry,
Behavioral Science, and
Psychology
The University of Kentucky
Sanders-Brown Center on
Aging - Clinical Studies uses
MemTrax
Mary Carter Award recipient
for his work with patients
with neurodegenerative
disease
https://ukhealthcare.uky.edu/
doctors/frederick-schmitt
Dr. Babak Kateb
Founding Chairman of the Board of
Society for Brain Mapping and
Therapeutics and The Brain Mapping
Foundation
Director of Brain Technology and
Innovation Park
Associate Editor for The Journal of
Alzheimer’s Disease
https://www.worldbrainmapping.org/A
bout/Babak-Kateb
4. Decentralized Clinical Trials
Combining specific variables associated with
cognition in conjunction with Machine
Learning components to discover new
understanding of the Human Brain.
Big data analysis with AI is the most logical
path forward to breakthroughs in the field.
● Since the beginning of the
COVID-19 pandemic there has been
an increase in demand for remote
testing
● Long term adaptation for more
efficient research, Longitudinal
● On site trials are expensive and time
consuming limiting the number of
participants
● More appealing to Pharma and
Biotech companies
Demand for Remote Assessment
5. MemTrax Scientific Advisory Board
J. Wesson Ashford M.D.,
Ph.D.
Authored over 160 publications
on Alzheimer’s disease and 10
demonstrating the effectiveness
of MemTrax
Department of Psychiatry &
Behavioral Sciences, Stanford
University
Director, War-Related Illness and
Injury Study Center at the Palo
Alto campus of the VA Palo Alto
Dr. Michael Bergeron
Artificial Intelligence and
Machine Learning Research
Clinical & Scientific Advisor
Sport Sciences & Medicine,
WTA Women's Tennis
Senior Vice President of
Development & Applications
of SIVOTEC Analytics
American College of Sports
Medicine (ACSM) – Fellow
Dr. Xianbo Zhou
Pharmaceutical Executive at
SJN Biomed
27 years research
experience in Biochem
General Manager of SJN
Biomed
Professor and Founding
Director of the Center for
Alzheimer’s Disease
Research at Washington
Institute of Clinical Research
George Perry M.D., Ph.D.
Editor and Chief of The Journal of
Alzheimer’s Disease
Determining the sequence of
events leading to neuronal
oxidative damage
University Chair in Neurobiology at
The University of Texas at San
Antonio
Dr. Frank Tarpin-Bernard
Founder and shareholder of the
Scientific Brain Training
company, France
Professor in Computer Science
at the National Institute of
Applied Science of Lyon
Published numerous
peer-reviewed journal articles
and book chapters
6. Demand is Increasing for Brain Health Programs
Expected dramatic increase in the number of people with dementia worldwide
Source: Alzheimer’s Disease International, World Alzheimer Report
7. Associated Care Costs Will Rise Proportionately
Currently Alzheimer’s Disease is the 3rd most expensive disease in the US
Source: Alzheimer’s Association, Changing the Trajectory of Alzheimer’s Disease: How Treatment by 2025 Saves Lives and Dollars
$
226
B
$
1.1
T
8. FDA approves first
Alzheimer’s disease drug
Aduhelm
(Aducanumab-avwa)
Biogen Pharmaceutical
“In clinical trials, ADUHELM reduced amyloid beta
plaques by 59 to 71 percent at 18 months of treatment”
● Establish Baseline Scores
● Regular Scheduled Testing
● Identify Changes Early
● Determine Memory and Cognitive
changes from Drugs or Diseases
including COVID-19
Drug Efficiency Testing
9. • Empowering everyone's brain health
• Simple translatable format
• Providing telehealth brain assessment
• Easy accessibility for
underrepresented populations
• Measuring brain treatment outcomes
• Lowering risk from brain-related issues
MemTrax Delivers a Better Brain Assessment
Creating new opportunities for a global community
10. Current tests have limited ability for
individuals, healthcare providers and
researchers to precisely measure &
monitor memory
Problems we Solve
• Large practice effects over time
• Lack precision of analysis
• Require trained experts to administer
• Require special equipment/environment
• Time intensive (for rater and subject)
• Not tech or mobile friendly
• Limited, or no ability to customize
New Brain Assessments are Needed
11. Accessible and Easy Brain Health Monitoring
Driving toward a world with better brain health treatment
Open Repeatable
Engaging
Quick Inclusive
Customizable
Available on all devices
Only takes about 2
minutes per session
Easy and intuitive for
everyone to use
Accurate long-term
performance tracking
Millions of unique test
permutations
Adjustable for clinicians
& researchers
12. How the MemTrax Assessment Works
User navigates to
test
Test downloaded
client-side from server
User starts test
(3s count down)
Instructions presented
User recognizes repeat
pictures & responds
Results sent back to server
(displaying results optional)
14. MemTrax Board of Advisors
Curtis Ashford
Managing member
MemTrax LLC
Produced MemTrax
self scoring design
Connecting people
around the world to
better understand
the Human Brain
Chris Outwater
CEO Liberty Access
Innovative device
development
Early adoption of
MemTrax
Nick Larson
General Partner at
Driven Capital
Social Media
Networking and
Marketing
Investor Relations
Lee S. Manela
MemTrax Developer
eCommerce and
CMS based web-site
Master
Manages multiple
$1M+ revenue sites
Robby McCullough
GoDaddy Partnership
Co-Founder of Beaver
Builder for Wordpress
Startup success
achieved | Over 40
active employees
Franklin Lowe
Healthcare Account
Director
MBA in Marketing
HIPAA certification
10 years healthcare
marketing with
senior populations
Pete Martinez
IBM Vice President of
Global Business
Services | 32 Years
Research at MIT Mass.
Institute of Technology
Big Data Analytics
CEO of SIVOTEC
Bioinformatics
https://www.linkedin.c
om/in/pete-martinez-4
803174/
https://www.linkedin.
com/in/franklinlowe/
https://www.linkedin.
com/in/lee-manela-0
6895118/
https://www.linkedin.
com/in/nlarson1/
https://www.linkedin.
com/in/chris-outwate
r-96115a2/
https://www.linkedin.
com/in/memtrax/
https://www.linkedin.
com/in/robmcculloug
h/
15. A Sample of Our Data
UCSF Brain Health Registry data, includes >10,000 participants
16. Other
• CANS-MCI
• CAMCOG / CANTAB
• CAMCI
• CogState
• CST (Computerized Self Test)
• IN/WN (IntegNeuro/WebNeuro)
• Mindstreams (NeuroTrax)
• MC-CARE
• Staying Sharp (AARP)
Computerized cognitive tests
• Easier to administer––established
model of self-administration
• Works across platforms
• Faster to administer
• More precise in measurement of
episodic memory
• Better ability to track memory
performance over time
MemTrax Advantage
Easy, quick, and longitudinal
17. Continued Innovation for Measuring Brain Health
Assessments to
measure more brain
health domains
MemTrax Roadmap
PRO
Professional version
for healthcare &
research administration
Advanced user
analytics & AI
retracement modeling
of AD
Native apps for
iOS & Android
(Completed 9/21)
18. Sports concussion
Alcohol or drug abuse
Medication change
Mood / Depression
Sleep
Age
Dementia
Alzheimer’s disease
Long COVID-19
Vehicle accident
Combat concussion
Poor diet
Lack of exercise
Loud noises
Smoking
Isolation
Consider All Brain Changing Events
Use cases for MemTrax
20. Publications and Research Inclusions
• Bredeson D. E. (2014). Reversal of cognitive decline: A novel therapeutic
program. Aging. 6(9): 707-717.
• Martin, Rose, et al. (2011). Reliability of Online MemTrax Digital Photo
Recognition, Word Recognition and H-Scan Screening Tests. Poster
presentation at the Alzheimer's Researchers' Symposium, Stanford
University.
• Ashford J. W., Gere E., & Bayley P. J. (2011). Measuring Memory in Group
Settings Using a Continuous Recognition Test. Journals of Alzheimer's
Disease. 27(4): 885-895.
• Ashford, J. W., et al. "P3-106: Screening for memory problems in a large
group setting." Alzheimer's & Dementia 4.4 (2008): T549-T550.
• Ashford, J. "MemTrax (Computerized Memory Screen)." American
Association for Geriatric Psychiatry Annual Meeting. New Orleans, LA, USA.
2007.
• Belden, Christine M., et al. "P3-108: Subjective memory complaints in the
healthy elderly." Alzheimer's & Dementia 4.4 (2008): T550-T551.
Published Works
• Bergeron MF, et al. (2020) Utility of MemTrax and Machine Learning Modeling in
Classification of Mild Cognitive Impairment. JAD;77(4):1545
• Weiner MW, et al. (2018) The Brain Health Registry: An internet-based platform for
recruitment, assessment, and longitudinal monitoring of participants for
neuroscience studies. Alzheimer’s Dement.Aug;14(8):1063-1076
• Ashford JW, et al. (2019)The MemTrax Test Compared to the Montreal Cognitive
Assessment Estimation of Mild Cognitive Impairment.
• Bergeron MF, et al. (2019)Episodic-Memory Performance in Machine Learning
Modeling for Predicting COgnitive Health Status Classification. JAD70(1):277-286
• Zhou X, et al. (2019) Advances in screening instruments for Alzheimer’s disease.
Aging Med.May 31;2(2):88-93
• Liu X, et al. (2021) Validity of the MemTrax Memory Test compared to the Montreal
Cognitive Assessment in the Detection of Mild Cognitive Impairment and Dementia
due to Alzheimer’s Disease in a Chinese Cohort. JAD80(3):1257-1267
• Weiner MW, et al. (2019) Cognitive Performance in Parkinson’s Disease in the
Brian Health Registry. JAD68(3):1029-1038
• Ashford CB, et al. (2019) A Computerized Continuous-Recognition Task for
Measurement of Episodic Memory. JAD69(2):385-399
21. Publications and Research Inclusions
• UCSF Brain Health Registry includes MemTrax in cognitive testing battery along with self-report data
(>100K participants)
• Alzheimer’s Foundation of America using MemTrax at https://afamemorytest.com/
• University of Wageningen (Netherlands) testing against MoCA for examining the role of nutrients in
cognition
• University of Kentucky, Sanders Brown Center on Aging
• Analyzing MemTrax data from over 2,000 individuals to norm across age bands, gender and education
levels
Ongoing Studies